In an observational study involving 24,290 individuals with T2DM taking SGLT2 inhibitors, Kristensen et al. reported that SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists (81). The gene discussed is GLP1R; the disease is nephrolithiasis.